Clicky

180 Life Sciences Corp.(ATNF)

Description: 180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.


Keywords: Biotechnology Clinical Medicine Disease Pain Immunology Inflammation Inflammatory Diseases Fibrosis Cytokine Animal Physiology Human Physiology Tumor Necrosis Factor

Home Page: 180lifesciences.com

ATNF Technical Analysis

Building 4
Palo Alto, CA 94306
United States
Phone: 650 507 0669


Officers

Name Title
Dr. James N. Woody M.D., Ph.D. CEO & Director
Mr. Ozan Pamir C.F.A. Interim CFO & Sec.
Mr. Quan Anh Vu COO & Chief Bus. Officer
Dr. Jonathan B. Rothbard Ph.D. Chief Scientific Officer
Dr. Raphael Mechoulam Ph.D. Co-Founder & Member of Scientific Advisory Board
Mr. Jason Assad Director of IR
Prof. Jagdeep Nanchahal Chief Medical Officer & Chairman of Clinical Advisory Board

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 6.079
Trailing PE: 5.6322
Price-to-Book MRQ: 0.4505
Price-to-Sales TTM: 0
IPO Date: 2017-06-27
Fiscal Year End: December
Full Time Employees: 0
Back to stocks